非小细胞肺癌原发灶与转移淋巴结中MDR-1、RRM-1、EGFR、ERCC-1的表达差异  

Differential expressions of MDR-1,RRM-1,EGFR and ERCC-1 in primary tumors and metastatic lymph nodes of NSCLC patients

作　　者：郭楠楠[1] 李珊珊[2] 张文[1] 于长海[1] 王宏伟[3] 张宜明[1] 俞建琦[1] 

机构地区：[1]解放军总医院第一附属医院胸心外科,北京100048 [2]解放军第309医院西山门诊部,北京100091 [3]解放军总医院第一附属医院病理科

出　　处：《细胞与分子免疫学杂志》2013年第8期870-873,共4页Chinese Journal of Cellular and Molecular Immunology

基　　金：2010~2011年度吴阶平医学基金会癌症靶向治疗研究基金(320.6750.12199)

摘　　要：目的研究非小细胞肺癌(NSCLC)原发灶和转移淋巴结中多药耐药蛋白(MDR-1)、核糖核苷酸还原酶M1(RRM-1)、表皮生长因子受体(EGFR)、错配切除修复蛋白1(ERCC-1)表达的差异,并分析这些表达差异性与临床病理类型的关系。方法采用免疫组织化学染色观察46例NSCLC原发灶及转移淋巴结中MDR-1、RRM-1、EGFR、ERCC-1蛋白的表达情况,用Wilcoxon秩和检验来比较原发灶和淋巴结转移灶表达是否存在差异,用Fisher检验分析差异性是否与病理类型相关。结果 46例各种病理类型的NSCLC,原发病灶与转移淋巴结均存在MDR-1、RRM-1、EGFR、ERCC-1表达,其中ECRR-1的表达差异在腺癌中具有统计学意义(P=0.026),而MDR-1,RRM-1,EGFR的差异性在各病理类型无统计学意义(P>0.05)。结论 MDR-1、RRM-1、EGFR、ERCC-1在NSCLC的原发病灶和转移淋巴结中均表达,但只有ERCC-1在肺腺癌原发灶与转移淋巴结的表达具有明显差异。Objective To investigate the differential expressions of multidrug resistance protein 1 （ MDR-1 ）, ribonucleoti- de reductase MI （RRM-1）, epidermal growth factor receptor（ EGFR）, excision repair cross-complementation group 1 （ ER-CC-1 ） in primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer （NSCLC）, and analyze the relationgship between the differential expressions and pathological types of NSCLC. Metheds The expressions of MDR-1, RRM-1, EGFR and ERCC-1 were detected by immunohistochemistry in primary tumors and metastatic lymph nodes of 46 cases NSCLC patients. WUcoxon signed ranks test was used to compare the differences in the expressions of these four molecular markers in primary lesions and metastatic lymph nodes. Fisher＇s exact test was used to analyze the relationgship between differential expressions and pathological types of NSCLC. Restdts The expressions of MDR-1, RRM-1, EGFR, ERCC-1 were observed in a variety of pathological types of NSCLC. The expression of ERCC-1 was signinifcantly different between primary tumors and metastatic lymph nodes for lung adenocarcinoma （P = 0.026）. But the expressions of MDR-1, RRM-1, EGFR were not signinifcantly different between primary tumors and metastatic lymph nodes for all pathological types of NSCLC （P〉0.05）. Conclusion The expression of MDR-1, RRM-1, EGFR, ERCC-1 of primary tumors and metastatic lymph nodes is found in all NSCLC. The expression of ERCC-1 is signinifcantly different in primary tumors from in metastatic lymph nodes of lung adenocarcinoma.

关 键 词：非小细胞肺癌 原发肿瘤 转移淋巴结 多药耐药蛋白 核糖核苷酸还原酶M1 表皮生长因子受体 剪切修复交叉互补基因1 

分 类 号：R392-33[医药卫生—免疫学] R734.2[医药卫生—基础医学]